Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Radius Health, Inc.
Radius Health, Inc. News
Radius Health, Inc. Quantitative Score
About Radius Health, Inc.
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
Radius Health, Inc. Earnings & Revenue
Radius Health, Inc. Financials
Table Compare
Compare RDUS metrics with: | |||
|---|---|---|---|
Earnings & Growth | RDUS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | RDUS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | RDUS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | RDUS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Radius Health, Inc. Income
Radius Health, Inc. Balance Sheet
Radius Health, Inc. Cash Flow
Radius Health, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Radius Health, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.7500 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2024-08-05 | 0.1875 | Quarterly |
| 2024-05-06 | 0.1875 | Quarterly |
| 2024-02-20 | 0.1875 | Quarterly |
| 2023-11-27 | 0.1875 | Quarterly |
| 2023-07-31 | 0.1875 | Quarterly |
Historical Market Cap
Shares Outstanding
Radius Health, Inc. Executives
| Name | Role |
|---|---|
| Ms. Tamara L. Lundgren J.D. | Chairman, President & Chief Executive Officer |
| Mr. Richard D. Peach | Executive Vice President & Chief Strategy Officer |
| Mr. James Matthew Vaughn | Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer |
| Mr. Erich D. Wilson | Senior Vice President, Chief HR Officer & Chief of Corporate Operations |
| Mr. Robert Stone | Vice President of Corporate Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Tamara L. Lundgren J.D. | Chairman, President & Chief Executive Officer | Female | 1958 | 1.63M |
| Mr. Richard D. Peach | Executive Vice President & Chief Strategy Officer | Male | 1964 | 906.14K |
| Mr. James Matthew Vaughn | Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer | Male | 1973 | 903.84K |
| Mr. Erich D. Wilson | Senior Vice President, Chief HR Officer & Chief of Corporate Operations | Male | 1969 | -- |
| Mr. Robert Stone | Vice President of Corporate Development | Male | -- |
Radius Health, Inc. Insider Trades
| Date | 6 May |
| Name | SUTHERLIN MICHAEL W |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 526.156 |
| Date | 6 May |
| Name | SHOEMAKER LESLIE L |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 56.058 |
| Date | 6 May |
| Name | MINOR GLENDA J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 122.974 |
| Date | 6 May |
| Name | Jahnke David L |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 667.033 |
| Date | 6 May |
| Name | Hunter Rhonda D |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 295.013 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 6 May | SUTHERLIN MICHAEL W | Director | Acquired | A-Award | 526.156 |
| 6 May | SHOEMAKER LESLIE L | Director | Acquired | A-Award | 56.058 |
| 6 May | MINOR GLENDA J | Director | Acquired | A-Award | 122.974 |
| 6 May | Jahnke David L | Director | Acquired | A-Award | 667.033 |
| 6 May | Hunter Rhonda D | Director | Acquired | A-Award | 295.013 |